After a 3-year hiatus, the American Association of Pharmaceutical Scientists (AAPS) 2022 PharmSci 360 will mark the in-person return of one of the largest and most influential pharmaceutical industry conferences of the year. At the Boston Convention and Exhibition Center in Boston, MA from October 17-19th, Crystal Pharmatech will be advancing the scientific conversation as they meet with industry players, buyers, and suppliers from around the world. As a leading expert in solid-state CRO services and formulation CDMO services, Crystal Pharmatech will contribute its unique expertise in API development supply chain to the discussions on the future of pharma.
Conferences like PharmSci 360 play a vital role in improving global health by facilitating the exchange of research and ideas from thousands of scientists and industry experts. Crystal Pharmatech contributes to the advancement of novel pharmaceutical solutions by providing biotechs with critical services and decades of expertise to move molecules from the lab to the clinic.
At Booth 320, attendees will have the opportunity to learn why hundreds of biotechs around the world turn to Crystal Pharmatech to solve their form and formulation challenges.
Technological proficiency, combined with decades of trusted experience, is the reason clients turn to Crystal Pharmatech when they run into challenges such as:
Uncertainties with form and formulation risks
Determining the necessity of a salt/co-crystal
Achieving desired tox exposures
Accelerating to FIH
Robert Wenslow, Ph.D., Crystal Pharmatech’s Vice President of Business Development expressed his guiding principle:
“Successful and efficient decisions on Phase I salt form and formulation are now routinely determined in the industry using novel technology combined with benchmarking. If partnering with Crystal Pharmatech before animal PK studies, there is no more need for a random walk that wastes time and resources. We utilize a data-driven, multi-disciplinary approach based on institutional knowledge, innovative technology, and comparative analysis to provide best-in-class form and formulation decisions.”
This mindset translates to a range of advanced capabilities available to the company’s clients:
Innovative PBPK model simulation
Polymorph, co-crystal, and solubility prediction software
Automated pKa and Log P determination on <5mg of material
Crystal Pharmatech recently opened Crystal Formulation Services (CFS), a novel, small molecule and formulation CDMO located in Suzhou, China. Chief Technology Officer of CFS, Xiaoxia (Jessica) Chen, Ph.D., will be joining booth 320 to provide consultation and guidance on how to develop your API in the most bioavailable, scalable, robust, and stable formulation for clinical development.
CFS compliments the North American formulation development partnership with Candoo Pharmatech Company Inc.. With the recent expansion, Crystal Pharmatech now utilizes 120,000 sq.ft. of R&D and GMP facility space across New Jersey, USA; Ontario, Canada; and Suzhou, China.
Among many additional capabilities, Crystal Pharmatech CRO and CDMO services cover:
API form and solid-state research
NCE drug product development
Within the conference at Booth 320 at 3pm on Monday, October 17th, Crystal Pharmatech will be hosting a Beer & Wine Happy Hour discussion to share their newest capabilities and engage with industry innovators who encounter these challenges. The conversation will continue for the full duration of 2022 PharmSci 360.
Wenslow will be joined by Senior Scientist Mitulkumar (Mitul) Patel, Ph.D., Head of Marketing Mailisi Heshuote, M.S., and their collaborative partners that provide a blanket of services covering all CRO and CDMO needs encountered by biotechs.
Any interested party can schedule a consultation with a Business Development Subject Matter Expert at this meeting link. Walk-up conversations are also encouraged, and you can meet your future form and formulation solutions partner at Booth 320.
For further information, follow and stay updated at the Crystal Pharmatech LinkedIn page.